Pharmacokinetics and tolerability of intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%) in 19 subjects with mild to severe renal impairment: terminal half life and peak concentration (C(max))remain unaffected

Detalles Bibliográficos
Autores principales: Jungheinrich, C, Scharpf, R, Wargenau, M, Bepperling, F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2001
Materias:
Meeting Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3333305/
http://dx.doi.org/10.1186/cc1185
_version_ 1782230419602669568
author Jungheinrich, C
Scharpf, R
Wargenau, M
Bepperling, F
author_facet Jungheinrich, C
Scharpf, R
Wargenau, M
Bepperling, F
author_sort Jungheinrich, C
collection PubMed
description
format Online
Article
Text
id pubmed-3333305
institution National Center for Biotechnology Information
language English
publishDate 2001
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-33333052012-04-24 Pharmacokinetics and tolerability of intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%) in 19 subjects with mild to severe renal impairment: terminal half life and peak concentration (C(max))remain unaffected Jungheinrich, C Scharpf, R Wargenau, M Bepperling, F Crit Care Meeting Abstract BioMed Central 2001 2001-03-02 /pmc/articles/PMC3333305/ http://dx.doi.org/10.1186/cc1185 Text en
spellingShingle Meeting Abstract
Jungheinrich, C
Scharpf, R
Wargenau, M
Bepperling, F
Pharmacokinetics and tolerability of intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%) in 19 subjects with mild to severe renal impairment: terminal half life and peak concentration (C(max))remain unaffected
title Pharmacokinetics and tolerability of intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%) in 19 subjects with mild to severe renal impairment: terminal half life and peak concentration (C(max))remain unaffected
title_full Pharmacokinetics and tolerability of intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%) in 19 subjects with mild to severe renal impairment: terminal half life and peak concentration (C(max))remain unaffected
title_fullStr Pharmacokinetics and tolerability of intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%) in 19 subjects with mild to severe renal impairment: terminal half life and peak concentration (C(max))remain unaffected
title_full_unstemmed Pharmacokinetics and tolerability of intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%) in 19 subjects with mild to severe renal impairment: terminal half life and peak concentration (C(max))remain unaffected
title_short Pharmacokinetics and tolerability of intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%) in 19 subjects with mild to severe renal impairment: terminal half life and peak concentration (C(max))remain unaffected
title_sort pharmacokinetics and tolerability of intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%) in 19 subjects with mild to severe renal impairment: terminal half life and peak concentration (c(max))remain unaffected
topic Meeting Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3333305/
http://dx.doi.org/10.1186/cc1185
work_keys_str_mv AT jungheinrichc pharmacokineticsandtolerabilityofintravenousinfusionofthenewhydroxyethylstarch130046in19subjectswithmildtosevererenalimpairmentterminalhalflifeandpeakconcentrationcmaxremainunaffected
AT scharpfr pharmacokineticsandtolerabilityofintravenousinfusionofthenewhydroxyethylstarch130046in19subjectswithmildtosevererenalimpairmentterminalhalflifeandpeakconcentrationcmaxremainunaffected
AT wargenaum pharmacokineticsandtolerabilityofintravenousinfusionofthenewhydroxyethylstarch130046in19subjectswithmildtosevererenalimpairmentterminalhalflifeandpeakconcentrationcmaxremainunaffected
AT bepperlingf pharmacokineticsandtolerabilityofintravenousinfusionofthenewhydroxyethylstarch130046in19subjectswithmildtosevererenalimpairmentterminalhalflifeandpeakconcentrationcmaxremainunaffected

Ejemplares similares